RFG Advisory LLC Buys 7,530 Shares of Tempus AI, Inc. $TEM

Key Points

• RFG Advisory LLC increased its stake in Tempus AI by 19.9%, acquiring 7,530 additional shares, bringing its total holdings to 45,372 shares valued at approximately $2.88 million.
• Major institutional investors, including Vanguard Group and ARK Investment Management LLC, have significantly increased their positions in Tempus AI, reflecting a growing interest in the company.
• Analysts have set varied price targets for Tempus AI, with Morgan Stanley raising its target to $68 and Needham & Company maintaining a Buy rating with a target of $70, while the average price target stands at $71.83.

RFG Advisory LLC lifted its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 19.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,372 shares of the company's stock after buying an additional 7,530 shares during the period. RFG Advisory LLC's holdings in Tempus AI were worth $2,883,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in TEM. Vanguard Group Inc. boosted its stake in shares of Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after buying an additional 5,900,668 shares during the period. ARK Investment Management LLC boosted its stake in shares of Tempus AI by 35.9% in the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after buying an additional 1,981,755 shares during the period. Nikko Asset Management Americas Inc. lifted its stake in Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock worth $205,401,000 after purchasing an additional 1,021,460 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after purchasing an additional 1,016,384 shares during the last quarter. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new stake in Tempus AI during the first quarter worth $34,119,000. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TEM shares. Morgan Stanley upped their target price on Tempus AI from $65.00 to $68.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Tempus AI in a research note on Wednesday, October 8th. Piper Sandler restated a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. Needham & Company LLC restated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research note on Friday, August 8th. Finally, HC Wainwright upped their target price on Tempus AI from $90.00 to $98.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI currently has an average rating of "Hold" and an average price target of $71.83.

Insiders Place Their Bets

In related news, CFO James William Rogers sold 7,528 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $561,965.20. Following the completion of the sale, the chief financial officer directly owned 138,473 shares in the company, valued at $10,337,009.45. This represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction on Monday, October 6th. The shares were sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the sale, the chief operating officer owned 130,000 shares of the company's stock, valued at $12,001,600. The trade was a 3.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 933,662 shares of company stock valued at $68,070,993 over the last ninety days. 26.27% of the stock is currently owned by corporate insiders.

Tempus AI Stock Down 4.9%

Shares of NASDAQ:TEM opened at $89.87 on Wednesday. The company has a fifty day moving average of $80.27 and a 200-day moving average of $65.36. The company has a market capitalization of $15.61 billion, a PE ratio of -75.52 and a beta of 4.87. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. Tempus AI, Inc. has a 52-week low of $31.36 and a 52-week high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company's revenue for the quarter was up 89.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. On average, equities analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.